Navigation Links
Novus Biologicals Hires David Eansor to Lead New Corporate-Development Effort
Date:1/24/2013

LITTLETON, Colo., Jan. 24, 2013 /PRNewswire/ -- Novus Biologicals LLC, a leading provider of antibodies and reagents to the life science research community, has hired David Eansor to lead a new corporate-development effort.

Eansor, a 13-year veteran in the life science market who was most recently the president of Thermo Fisher Scientific's bioscience division, joined Novus in January as senior vice-president of corporate development. In this new role, Eansor is tasked with accelerating Novus' already impressive growth through a combination of organic investments, licensing and acquisitions of complementary products and capabilities.

"I'm thrilled to join Novus, and for the opportunity to create new growth platforms for this innovative company," Eansor said. "I have watched Novus grow from a niche player to a leader in its space, and I've always been impressed with its commitment to scientific research and outstanding customer service."

"We are so pleased to have an executive of David's caliber join our team, and look forward to many stellar contributions as he expands this critical corporate-development function for us," added Karen Padgett , Novus' founder and chief executive.

Before becoming president of the bioscience division of Thermo Fisher , a publicly traded company, Eansor served as president of the life science research division, acquiring three businesses during his tenure.

Prior to that, he was president of Cambrex Bioproducts, another life science research business focused on cell biology. Eansor also spent 19 years with R.P Scherer Corp., a contract pharmaceutical drug-delivery manufacturer which was acquired by Cardinal Health. He holds a degree in chemistry from the University of Western Ontario as well as a bachelor of commerce and an MBA from the University of Windsor, also in Ontario, Canada.

About Novus

Novus Biologicals is a leading digital marketing-driven, life science company that supplies antibodies and reagents to the $6 billion global proteomics market.  Novus is known for its breadth of quality antibodies and reagents that are well recognized by its global customer base.  Based in Littleton, CO, the company was founded in 1996 to license, produce and market antibodies to support niche and emerging areas of research.  Now Novus is a global enterprise with a catalog of 180,000 products sold in 60 countries, mainly through its Web site. Novus is backed by Mainsail Partners, a San Francisco growth-equity firm, and has additional offices in Ontario, Canada and Cambridge, UK.

CONTACT

Karen Padgett , President and CEO

Novus Biologicals, LLC

Karen@novusbio.com

303-730-1950

www.novusbio.com


'/>"/>
SOURCE Novus Biologicals LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
2. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
3. PathoGenetix Hires Food Safety Testing Expert John W. Czajka as Vice President of Business Development
4. Ganeden Biotech Hires New Marketing Manager
5. Provia Labs Hires Vice President of International Business Development to Expand Global Distribution for its Stem Cell Banking Service and Biobanking Products
6. Ernst & Young LLP Bolsters Fraud Investigation & Dispute Services with New Hires and Promotions
7. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
8. Textile Company PurThread Technologies Opens Headquarters in Durham, North Carolina and Hires New Senior Staff
9. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
10. Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer
11. David Smith Named Vice President of Operations for HealthTell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
Breaking Biology News(10 mins):